18:08 EST Janux Therapeutics (JANX) down 46% at $18.50 after JANX007 Phase 1 data in mCRPC
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics reports ‘positive’ updated interim data for JANX007
- Promising Potential of Janux Therapeutics: Buy Rating on Strong Clinical and Growth Prospects
- Janux Therapeutics initiated with a Peer Perform at Wolfe Research
- Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position
- Janux Therapeutics price target raised to $46 from $45 at Stifel